ACE Report Cover
Duloxetine comparable to current pain relief methods in treating chronic low back pain
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
SPINE
Duloxetine comparable to current pain relief methods in treating chronic low back pain .
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2014;2(1):23 Eur Spine J. 2013 Sep;22(9):1996-2009
Autori che hanno contribuito

H Cawston A Davie MA Paget V Skljarevski M Happich

Fifteen randomized clinical trials were included in this meta-analysis to compare duloxetine to a variety of other pain medications in the treatment of chronic low back pain. Comparisons between duloxetine and antidepressants, cox-2 inhibitors, non-scheduled opioids, scheduled opioids and other drugs suggested that scheduled opioids were more effective than duloxetine; however, the effect size was minimal and difference was lost when repeated using a random effects model. Before any definitive conclusions can be made regarding duloxetine as an alternative treatment for chronic low back pain, further clinical trials providing direct comparisons are required.


Dettagli sul finanziamento della pubblicazione +
Finanziamento:
Industry funded
Sponsor:
Eli Lilly and Company
Conflitti:
Other

Rischio di pregiudizio

9,5/10

Criteri di segnalazione

18/20

Indice di fragilità

N/A

Were the search methods used to find evidence (original research) on the primary question or questions stated?

Was the search for evidence reasonably comprehensive?

Were the criteria used for deciding which studies to include in the overview reported?

Was the bias in the selection of studies avoided?

Were the criteria used for assessing the validity of the included studies reported?

Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?

Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?

Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?

Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?

How would you rate the scientific quality of this evidence?

Sì = 1

Incerto = 0,5

Non rilevante = 0

No = 0

La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.

4/4

Introduction

4/4

Accessing Data

3/4

Analysing Data

4/4

Results

3/4

Discussion

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.

Perché questo studio era necessario ora?

Chronic low back pain is a common musculoskeletal disorder that contributes to growing disability rates, and results in a substantial economic burden on the healthcare system. Back pain can be caused by a number of factors, making it very difficult to determine an appropriate course of treatment. The majority of treatment strategies revolve around symptom relief including opioids, nonsteroidal anti-inflammatory drugs, anticonvulsants and antidepressants. Duloxetine regulates the descending pain inhibitory pathways by inhibiting serotonin epinephrine reuptake. This meta-analysis was necessary to make an indirect comparison of duloxetine and oral pharmacological therapies in the treatment of low back pain.

Qual era la domanda di ricerca principale?

Is duloxetine effective in relieving chronic low back pain compared to opioids, antidepressants, cox-2 inhibitors, and other drugs?

Caratteristiche dello studio +
Data Source:
A search of the following of the databases was conducted from 1966 to January 2011: PubMed, EMBASE, Cochrane and Centre for Reviews and Dissemination (CRD).
Index Terms:
['Low back pain' OR ('low' AND 'back' AND 'pain' OR 'low back pain'] AND ['Drug therapy' OR ('drug' AND 'therapy' OR 'drug therapy' OR 'drug therapy' OR ('drug' AND 'therapy')] AND ['Clinical trial' OR 'clinical trials as topic' OR 'clinical trials']
Study Selection:
Studies were screened by two independent authors and any discrepancies were mediated by a third reviewer. The fifteen included studies were randomized, written in English, double-blind, placebo-controlled trials of patients over 18 years old suffering from chronic low back pain for at least 3 months prior to the study and were. Exclusion criteria for studies included patients 18 years or younger, acute or pain for less than 3 months prior to study, or only one treatment arm was allocated to drug therapy.
Data Extraction:
Outcomes, study design synopsis, comparator therapies, dosing regimen, titration schedule, duration of treatment, baseline characteristics, and efficacy outcomes were summarized in an Excel spreadsheet by two independent authors and discrepancies were resolved by a third reviewer.
Data Synthesis:
Fixed and random effects normal models provided estimates of the mean difference in treatment effect. Pooled estimates of treatment difference in three-arm trials were used to calculate Cochrane Q tests, and I^2 statistics to test and quantify between-study heterogeneity. Forest plots were generated to visually assess the extent of heterogeneity. Small effect size was defined as standardized mean difference (SMD) from 0.2-0.5, moderate effect size as SMD from 0.5-0.8, and large effect size as SMD greater than 0.8.
Quali erano i risultati importanti?
  • Standardized mean differences were highest in studies assessing scheduled opioid treatment and in a the meta-analysis of 15 studies, the fixed effects model found scheduled opioids to be more effective than duloxetine; however, the effect size presented a less than small magnitude of effect and the difference was not found when assessed under a random effects model. Heterogeneity comparing non-scheduled opioids was 75%, scheduled opioids had a heterogeneity of 79% and all other drug classes had low heterogeneity.
  • Meta-analysis using a fixed effects model found that, with the exception of selective serotonin reuptake inhibitors and glucosamine, all drug classes were more effective than placebo.
  • Meta-analysis using a random effects model for indirect comparison between drug treatments resulted in antidepressants (SMD=0.28, 95%CI -0.33, 0.89), cox-2 inhibitors (SMD=-0.05, 95%CI -0.40, 0.30), non-scheduled opioids (SMD=-0.13, 95%CI -0.47, 0.20), scheduled opioids (SMD=-0.24, 95%CI -0.55, 0.05) and other drugs (SMD=0.22, 95%CI -0.29, 0.74) being similar to duloxetine (Between study variance = 0.04).
  • Pain duration was found to be a covariate according to a sensitivity analysis (SD=0.08, 95%CI 0.06, 0.38), with lower treatment differences observed for patients who had suffered pain for over 6 months.
Che cosa devo ricordare di più?

Duloxetine was found to be comparable to antidepressants, Cox-2 inhibitors, non-scheduled opioids and other drugs. Scheduled opioids were found to be more effective in the fixed effects model, however this benefit was not observed in the random effects model.

Come influenzerà l'assistenza ai miei pazienti?

Duloxentine did not prove to be more beneficial to patients with chronic low back than other drugs that are currently used. Limitations include a low number of studies for each comparison and a variety of outcome measures used in the studies. Also, these results are based on an indirect comparison, indicating the need for future research that make head-to-head comparisons of duloxetine with other drug treatments.

DISCLAIMER

Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.

0 di 4 articoli mensili GRATUITI sbloccati
Ha raggiunto il suo limite di 4 visualizzazioni di articoli gratuiti questo mese

Accesso a OrthoEvidence a soli 1,99 dollari a settimana.

Rimanga in contatto con le ultime prove. Può disdire in qualsiasi momento.
  • Valutazioni critiche dei più recenti studi randomizzati controllati ad alto impatto e delle revisioni sistematiche in ortopedia.
  • Accesso ai contenuti del podcast OrthoEvidence, tra cui collaborazioni con il Journal of Bone and Joint Surgery, interviste con chirurghi di fama internazionale e tavole rotonde su notizie e argomenti ortopedici.
  • Abbonamento a The Pulse, una newsletter bisettimanale basata sulle evidenze scientifiche, progettata per aiutarla a prendere decisioni cliniche migliori.
Upgrade
Close Dialog
Bentornato!
Ha dimenticato la password?
Inizi la sua prova gratuita oggi stesso!

Il suo account sarà affiliato a
e includerà l'accesso gratuito a OrthoEvidence


O
Ha dimenticato la password?

O
Controlli la sua e-mail

Se esiste un account con l'indirizzo e-mail fornito, le verrà inviata un'e-mail di reimpostazione della password. Se non vede l'e-mail, controlli la cartella spam o posta indesiderata.

Per ulteriore assistenza, contatti il nostro team di supporto.

Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Tradurre il Rapporto ACE

OrthoEvidence utilizza un servizio di traduzione di terze parti per rendere i contenuti accessibili in più lingue. Si prega di notare che, sebbene venga fatto ogni sforzo per garantire l'accuratezza, le traduzioni potrebbero non essere sempre perfette.

Come citare questo documento ACE Report

OrthoEvidence. Duloxetine comparable to current pain relief methods in treating chronic low back pain. OE Journal. 2014;2(1):23. Available from: https://myorthoevidence.com/AceReport/Show/duloxetine-comparable-to-current-pain-relief-methods-in-treating-chronic-low-back-pain

Copiare la citazione
Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Funzionalità per i membri Premium

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence Premium.

Condividi questo articolo ACE Report